Stock BAFNAPH BAFNA PHARMACEUTICALS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Bafna Pharmaceuticals Limited NSE India S.E.

Equities

BAFNAPH

INE878I01014

Pharmaceuticals

End-of-day quote NSE India S.E.
Other stock markets
 		5-day change 1st Jan Change
- INR -.--% Intraday chart for Bafna Pharmaceuticals Limited +697.75% +207.36%
Feb. 12 Bafna Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
2023 Bafna Pharmaceuticals Resumes Commercial Production of Manufacturing Units in Chennai, India MT

Valuation

Fiscal Period: Maart 2020 2021 2022 2023
Capitalization 1 31.46 3,252 2,996 1,940
Enterprise Value (EV) 1 -23.17 3,391 3,105 2,091
P/E ratio -0.13 x 55.9 x 58.4 x 17.1 x
Yield - - - -
Capitalization / Revenue 0.07 x 4.57 x 3.52 x 1.68 x
EV / Revenue -0.05 x 4.76 x 3.65 x 1.81 x
EV / EBITDA -1.8 x 31.9 x 26 x 12.2 x
EV / FCF 0.2 x -15.7 x -1,110 x -21.5 x
FCF Yield 507% -6.36% -0.09% -4.65%
Price to Book 0.06 x 5.73 x 4.76 x 2.64 x
Nbr of stocks (in thousands) 2,366 23,656 23,656 23,656
Reference price 2 13.30 137.4 126.6 82.00
Announcement Date 7/9/20 7/22/21 7/5/22 8/30/23
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: Maart 2018 2019 2020 2021 2022 2023
Net sales 1 480.3 436.4 424.7 712.2 851.4 1,153
EBITDA 1 -342.8 -129.8 12.86 106.2 119.4 171.1
EBIT 1 -381.2 -162.8 -19.8 61.46 64.43 117.7
Operating Margin -79.37% -37.31% -4.66% 8.63% 7.57% 10.21%
Earnings before Tax (EBT) 1 -147.2 -182.9 -18.83 58.27 51.51 116.2
Net income 1 -167.4 -198.8 -247.3 58.27 51.51 113.4
Net margin -34.85% -45.56% -58.22% 8.18% 6.05% 9.83%
EPS 2 -71.50 -123.9 -104.5 2.460 2.170 4.793
Free Cash Flow 1 30.1 27.94 -117.4 -215.8 -2.796 -97.3
FCF margin 6.27% 6.4% -27.64% -30.31% -0.33% -8.43%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 10/1/18 6/5/19 7/9/20 7/22/21 7/5/22 8/30/23
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net Debt 1 436 435 - 140 109 151
Net Cash position 1 - - 54.6 - - -
Leverage (Debt/EBITDA) -1.272 x -3.353 x - 1.316 x 0.912 x 0.8835 x
Free Cash Flow 1 30.1 27.9 -117 -216 -2.8 -97.3
ROE (net income / shareholders' equity) -42.6% -69.1% -5.38% 10.8% 8.61% 16.7%
ROA (Net income/ Total Assets) -15% -7.89% -1.3% 4.88% 4.56% 6.7%
Assets 1 1,112 2,519 19,062 1,195 1,130 1,693
Book Value Per Share 2 160.0 80.60 216.0 24.00 26.60 31.10
Cash Flow per Share 2 12.50 11.50 35.80 0.7600 0.0700 3.300
Capex 1 1.27 3.33 14.3 60.9 75.4 67.2
Capex / Sales 0.26% 0.76% 3.36% 8.56% 8.86% 5.82%
Announcement Date 10/1/18 6/5/19 7/9/20 7/22/21 7/5/22 8/30/23
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Generic Pharmaceuticals

1st Jan change Capi.
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+19.62% 43.34B
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+20.44% 21.96B
SANDOZ GROUP AG Stock Sandoz Group AG
+10.86% 14.09B
CIPLA LIMITED Stock Cipla Limited
+13.07% 13.64B
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+37.46% 11.43B
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-8.59% 6.86B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+8.46% 5.22B
Generic Pharmaceuticals
  1. Stock Market
  2. Equities
  3. BAFNAPH Stock
  4. BAFNAPH Stock
  5. Financials Bafna Pharmaceuticals Limited